Bristol Myers Squibb : JP Morgan Presentation

JP Morgan Presentation

January 10, 2022

Forward Looking Statements and Non-GAAP Financial Information

This presentation contains statements about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the Company's most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available on the SEC's website, on the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

This presentation includes certain non-generally accepted accounting principles (GAAP) financial measures that we use to describe our

company's performance. The non-GAAP information presented provides investors with additional useful information but should not be

considered in isolation or as substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

Also note that a reconciliation of forward-lookingnon-GAAP financial measures, however, is not provided due to no reasonably accessible or reliable comparable GAAP measures for such statements and the inherent difficulty in forecasting and quantifying such measures that are necessary for such reconciliation. Namely, we are not able to reliably predict the impact of certain specified items or currency exchange rates beyond the next twelve months. As a result, the reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is not available without unreasonable effort. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on our future GAAP results.

Not for Product Promotional Use

2

T H E B R I S T O L M Y E R S S Q U I B B S T O R Y

Strong Replacement Power Drives Growth Through the Decade

Expect growth through the decade

Powerful drivers underpin our growth

Continuing strong execution

Not for Product Promotional Use

3

Our Strategic Foundation

A differentiated biopharma company focused on innovative medicines for patients with cancer and other serious diseases

BEST OF BIOTECH BEST OF PHARMA

• Leading scientific innovation
• Collaborating at center of the biotech ecosystem
• Leveraging global scale and agility
• Driven by the best people

Not for Product Promotional Use

4

Our Journey of Transformation

2007 - 2013		2014 - 2018		Today

BioPharma Strategy Introduced	Focus on Specialty Medicines	Renewing the Portfolio
• Selective acquisitions and	• Pioneering Immuno-Oncology	• Deepening innovation engine
divestitures	• Divested diabetes business	• New product portfolio
• Focused exclusively on		launches
innovative medicines

Not for Product Promotional Use

5